ACA
PACB icon

Atlas Capital Advisors’s Pacific Biosciences PACB Stock Holding History

Atlas Capital Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,019
Closed -$3.12K – 718
2020
Q1 		$3.12K Buy
+1,019
New +$4.17K ﹤0.01% 641
2019
Q4 		– Sell
-77,891
Closed -$402K – 659
2019
Q3 		$402K Buy
77,891
+4,996
+7% +$27.9K 0.12% 215
2019
Q2 		$441K Sell
72,895
-1,055
-1% -$7.4K 0.14% 184
2019
Q1 		$535K Hold
73,950
– – 0.19% 139
2018
Q4 		$547K Buy
+73,950
New +$469K 0.22% 122

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $290M AUM 183.72% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Atlas Capital Advisors's PACB Position: Q2 2020 in Review

Atlas Capital Advisors sold out of Pacific Biosciences (PACB) in Q2 2020, closing a stake of 1,019 shares — an estimated $3.12K sold.

Atlas Capital Advisors first reported a position in PACB in Q4 2018 and held it in 5 quarters. The position peaked at $547K in Q4 2018. 151 funds tracked by Wall St. Rank hold PACB as of Q2 2020.

  • Atlas Capital Advisors reported no remaining Pacific Biosciences position as of Q2 2020 after selling out during the quarter.
  • Atlas Capital Advisors sold 1,019 Pacific Biosciences shares in Q2 2020, an estimated $3.12K.
  • Atlas Capital Advisors first reported a position in Pacific Biosciences in Q4 2018 and held it in 5 quarters.
  • Atlas Capital Advisors's Pacific Biosciences position peaked at $547K in Q4 2018.
  • 151 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2020.

Based on Atlas Capital Advisors's 13F filing for Q2 2020, filed 28 Jul 2020.